Breaking News

Correct: S&P 500 Extends Gain to Biggest Since 2013
Tweet TWEET

Reaxys® Significantly Expands its Content and Interface to Deliver Chemistry Information to Researchers Across Disciplines

 Reaxys® Significantly Expands its Content and Interface to Deliver Chemistry
                Information to Researchers Across Disciplines

  PR Newswire

  AMSTERDAM, April 8, 2013

AMSTERDAM, April 8, 2013 /PRNewswire/ --

Elsevier , a world-leading provider of scientific, technical and medical
information products and services, today announced a significant content
expansion and an improved and enriched user interface for Reaxys , a unique
chemistry workflow solution. With this interface and content update Reaxys now
supports the entire chemistry workflow resulting in a faster and more
efficient research process. Reaxys now encompasses over 16,000 periodicals and
has coverage of over 30 million reactions and over 500 million experimentally
measured data.

Designed by chemists for chemists, Reaxys enables researchers to advance
quickly and confidently through their workflow in order to deliver superior
outcomes. An independent survey of 200 users of the product found that the
research process was conducted on average 30 percent quicker with Reaxys, when
compared to existing alternatives; and related R&D costs were estimated to be
reduced by almost 25 percent.

"The pressure on chemists to deliver results is considerable whether they're
working in the public or private sector. Like in many other fields, the
quantity of data is increasing exponentially. Researchers do not have time to
read everything, so they need a solution that helps them to quickly find the
right information sources. 95 percent of the top global spenders in pharma use
Reaxys because it is flexible enough to accommodate, for example, all the
content that researchers need, displayed in one common user interface,
ensuring that they don't have to switch from one system to another," said Dr.
Jürgen Swienty-Busch, Director of Product Management for Reaxys. "The two most
critical things for our customers are innovation and efficiency. By embedding
the information they need into their workflow, whether in their E-lab notebook
to record experiments or by using an API to display results in a different
environment, Reaxys enables researchers to work more efficiently and progress
towards their innovation objectives."

"Reaxys' new content and capability expansion of the user interface expands
horizons for researchers across all chemistry related domains. Reaxys, in
combination with Reaxys Medicinal Chemistry, the domain specific solution,
enables users to make more confident decisions about compound selection and
synthesis much earlier in the process, improving the likelihood of developing
a successful drug and reducing the costs associated with a drug candidate
failure in the pre-clinical or clinical development stages," said Meeuwis van
Arkel, Vice President Product Development at Elsevier. "Reaxys is
interoperable with other innovative solutions which assist researchers across
disciplines; this interoperability is vital in promoting organizational
efficiency and R&D efficacy."

Reaxys is a key pillar of Elsevier Life Science Solutions, a suite of
interoperable, domain-specific, decision support tools which span the
discovery and development workflow. Reaxys works with solutions including;
ScienceDirect, for immediate full-text access; Scopus, for in-depth
bibliometric information; PharmaPendium for a comprehensive view into FDA/EMA
approved drugs.

To view Reaxys' new interface and for more information go to:
http://www.elsevier.com/reaxys

About Reaxys®

Reaxys® is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys® combines reaction and substance
data in organic, organometallic, inorganic and physical chemistry with
synthesis planning. Researchers can get the information they need in a single
overview, from source publications carefully selected for their importance and
relevance to research chemists. Elsevier continues to engage with the
chemistry community to ensure that Reaxys® continues to reflect how chemists
think and work. For more information please visit Reaxys .

Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier
Properties SA and used under license.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Suite ,
which enhance the productivity of science and health professionals, and the
SciVal suite and MEDai's Pinpoint Review , which help research and health care
institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC , a world leading
provider of professional information solutions in the Science, Medical, Legal
and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and
Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact Liz Griffioen Elsevier +31-20-485-2247 l.griffioen@elsevier.com
 
Press spacebar to pause and continue. Press esc to stop.